Ethologically based resolution of D2-like dopamine receptor agonist- versus antagonist-induced behavioral topography in dopamine- and adenosine 3′,5′-monophosphate-regulated phosphoprotein of 32 kDa "knockout" mutants congenic on the C57BL/6 genetic background

Journal of Pharmacology and Experimental Therapeutics

Volumn 310, Issue 3, 2004, Pages 1281-1287

  Nally, Rachel E ^a   Kinsella, Anthony ^b   Tighe, Orna ^a   Croke, David T ^a   Fienberg, Allen A ^c   Greengard, Paul ^c   Waddington, John L ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; EMONAPRIDE; N (3 HYDROXYPHENETHYL) N (PHENETHYL)PROPYLAMINE; PHOSPHOPROTEIN DARPP 32;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG PROTEIN BINDING; GENE DELETION; GROOMING; KNOCKOUT MOUSE; LOCOMOTION; MALE; MASTICATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REARING; TOPOGRAPHY;

ANIMALS; BENZAMIDES; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DOPAMINE ANTAGONISTS; FEMALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; PHENETHYLAMINES; PHOSPHOPROTEINS; RECEPTORS, DOPAMINE D2;

EID: 4243175862     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.068957     Document Type: Article

References (31)

1. Banbury Conference (1997) Mutant mice and neuroscience: recommendations concerning genetic background. Banbury Conference on genetic background in mice. Neuron 19:755-759.
2. Clifford JJ, Kinsella A, Tighe O, Rubinstein M, Grandy DK, Low MJ, Croke DT, and Waddington JL (2001) Comparative, topographically-based evaluation of behavioural phenotype and specification of D(1)-like:D(2) interactions in a line of incipient congenic mice with D(2) dopamine receptor 'knockout'. Neuropsychopharmacology 25:527-536.
3. Clifford JJ, Tighe O, Croke DT, Kinsella A, Sibley DR, Drago J, and Waddington JL (1999) Conservation of behavioural topography to dopamine D1-like receptor agonists in mutant mice lacking the D1A receptor implicates a D1-like receptor not coupled to adenylyl cyclase. Neuroscience 93:1483-1489.
4. Clifford JJ, Usiello A, Vallone D, Kinsella A, Borrelli E, and Waddington JL (2000) Topographical evaluation of behavioural phenotype in a line of mice with targeted gene deletion of the D2 dopamine receptor. Neuropharmacology 39:382-390.
5. Clifford JJ and Waddington JL (1998) Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach. Psychopharmacology 136:284-290.
6. Deutch AY and Roth RH (1990) The determinants of stress-induced activation of the prefrontal cortical dopamine system. Prog Brain Res 85:367-402.
7. Di Chiara G (2002) Dopamine in the CNS I. Springer, Berlin.
8. Euvrard C, Ferland L, Di Paolo T, Beaulieu M, Labrie F, Oberlander C, Raynaud JP, and Boissier JR (1980) Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levels. Neuropharmacology 19:379-386.
9. Fienberg AA and Greengard P (2000) The DARPP-32 knockout mouse. Brain Res Rev 31:313-319.
10. Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, Nishi A, Cheramy A, O'Callaghan JP, Miller DB, Cole DG, et al. (1998) DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science (Wash DC) 281:838-842.
11. Greengard P (2001) The neurobiology of slow synaptic transmission. Science (Wash DC) 94:1024-1030.
12. Greengard P, Allen PB, and Nairn AC (1999) Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23:435-447.
13. Hemmings HC Jr, Greengard P, Tung HY, and Cohen P (1984) DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature (Lond) 310:503-505.
14. Kalivas PW and Duffy P (1995) Selective activation of dopamine transmission in the shell of the nucleus accumbens by stress. Brain Res 675:325-328.
15. Kelly MA, Rubinstein M, Phillips TJ, Lessov CN, Burkhart-Kasch S, Zhang G, Bunzow JR, Fang Y, Gerhardt GA, Grandy DK, et al. (1998) Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background and developmental adaptations. J Neurosci 18:3470-3479.
16. Levant B (1997) The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 49:231-252.
17. McNamara FN, Clifford JJ, Tighe O, Kinsella A, Drago J, Croke DT, and Waddington JL (2003) Congenic D(1A) dopamine receptor mutants: ethologically based resolution of behavioural topography indicates genetic background as a determinant of knockout phenotype. Neuropsychopharmacology 28:86-99.
18. McNamara FN, Clifford JJ, Tighe O, Kinsella A, Drago J, Fuchs S, Croke DT, and Waddington JL (2002) Phenotypic, ethologically based resolution of spontaneous and D(2)-like vs D(1)-like agonist-induced behavioural topography in mice with congenic D(3) dopamine receptor "knockout". Synapse 46:19-31.
19. Nally RE, McNamara FN, Clifford JJ, Kinsella A, Tighe O, Croke DT, Fienberg AA, Greengard P, and Waddington JL (2003) Topographical assessment of ethological and dopamine receptor agonist-induced behavioral phenotype in mutants with congenic DARPP-32 'knockout'. Neuropsychopharmacology 28:2055-2063.
20. Niznik HB, Grigoriadis DE, Pri-Bar I, Buchman O, and Seeman P (1985) Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2. Naunyn-Schmiedeberg's Arch Pharmacol 329:333-343.
21. Phillips TJ, Hen R, and Crabbe JC (1999) Complications associated with genetic background effects in research using knockout mice. Psychopharmacology 147:5-7.
22. Ross SA, Wong JY, Clifford JJ, Kinsella A, Massalas JS, Horne MK, Scheffer IE, Kola I, Waddington JL, Berkovic SF, et al. (2000) Phenotypic characterization of an alpha 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. J Neurosci 20:6431-6441.
23. Sibley DR (1999) New insights into dopaminergic receptor function using antisense and genetically altered animals. Annu Rev Pharmacol Toxicol 39:313-341.
24. Sidhu A, Laruelle M, and Vernier P (2003) Dopamine Receptors and Transporters: Function, Imaging and Clinical Implications. Marcel Dekker, New York.
25. Svenningsson P, Lindskog M, Ledent C, Parmentier M, Greengard P, Fredholm BB, and Fisone G (2000) Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2 and adenosine A2A receptors. Proc Natl Acad Sci USA 97:1856-1860.
26. Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M, McKinzie DL, Fienberg AA, Nomikos GG, and Greengard P (2003) Diverse psychotomimetics act through a common signaling pathway. Science (Wash DC) 302:1412-1415.
27. Tomiyama K, McNamara FN, Clifford JJ, Kinsella A, Drago J, Fuchs S, Grandy DK, Low MJ, Rubinstein M, Tighe O, et al. (2004) Comparative phenotypic resolution of spontaneous, D2-like and D1-like agonist-induced orofacial movement topographies in congenic mutants with dopamine D2 vs. D3 receptor "knockout". Synapse 51:71-81.
28. Tomiyama K, McNamara FN, Clifford JJ, Kinsella A, Drago J, Tighe O, Croke DT, Koshikawa N, and Waddington JL (2002) Phenotypic resolution of spontaneous and D1-like agonist-induced orofacial movement topographies in congenic dopamine D1A receptor 'knockout' mice. Neuropharmacology 42:644-652.
29. Waddington JL, Clifford JJ, McNamara FN, Tomiyama K, Koshikawa N, and Croke DT (2001) The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion ('knockout'). Prog Neuropsychopharmacol Biol Psychiatry 25:925-964.
30. Waddington JL, Daly SA, Downes RP, Deveney AM, McCauley PG, and O'Boyle KM (1995) Behavioural pharmacology of 'D-1-like' dopamine receptors: further subtyping, new pharmacological probes and interactions with 'D-2-like' receptors. Prog Neuropsychopharmacol Biol Psychiatry 19:811-631.
31. Waddington JL, Daly SA, McCauley PG, and O'Boyle KM (1994) Levels of functional interaction between D1-like and D2-like dopamine receptor systems, in Dopamine Receptors and Transporters: Pharmacology, Structure and Function (Niznik HB ed) pp 511-537, Marcel Dekker, New York.